Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The British Journal of Surgery|July 6, 2010
Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancerM E Straver, C E Loo, T Alderliesten, et al.
European Journal of Cancer (Oxford, England : 1990)|May 26, 2009
Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancerM E Straver, E J Th Rutgers, N S Russell, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 9, 2012
Radioguided occult lesion localisation (ROLL) in breast-conserving surgery after neoadjuvant chemotherapyM Donker, M E Straver, E J Th Rutgers, et al.
The British Journal of Surgery|May 20, 2017
Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapyB B Koolen, M Donker, M E Straver, et al.
Annals of Surgical Oncology|April 8, 2010
The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapyM E Straver, E J Th Rutgers, S Rodenhuis, et al.
Annals of Surgical Oncology|March 8, 2018
Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI ProcedureM E M van der Noordaa, F H van Duijnhoven, M E Straver, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 6, 2008
[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]M E Straver, J C van Adrichem, E J Th Rutgers, et al.
The British Journal of Surgery|October 9, 2019
Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancerJ M Simons, M L M A van Pelt, A W K S Marinelli, et al.
Cancers|October 28, 2023
<sup>89</sup>Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility StudyD G J Linders, M M Deken, M A van Dam, et al.
Pageof 1